Nanri et al. found that cross-talk between the TGF-β and periostin axes is necessary for pulmonary fibrosis, and created an integrin αvβ3 receptor antagonist that attenuated fibroblast activation and has potential as a therapeutic agent for IPF33. The gene discussed is TGFB1; the disease is pulmonary fibrosis.